Universitätsmedizin Göttingen -
Abteilung Molekulare Onkologie, GZMB

 Employees: 11-50

GZMB - Department of Molecular Oncology

Director: Matthias Dobbelstein

Guest professor: Ute Moll

Junior professor: Steven Johnsen

We are focussing our research on the tumor suppressor p53, trying to elucidate its mechanisms of action, its regulation and its suitability as a target for cancer therapy. p53 operates as a transcription factor and prevents uncontrolled cell proliferation. This activity is regulated through a sophisticated regulatory network that responds to DNA damage. Despite our knowledge concerning the molecular biology of p53, an integrated concept of its regulation, and its translation into rational diagnostics and therapy, are still in their infancy. The tumor suppressor gene TP53 is mutated or deleted in approximately 50% of malignant tumors. However, this does not mean that p53 is active in the remaining cases. It appears that in the vast majority of the remaining 50% of tumors, p53 is inactivated through malfunction of its modulators, such as Mdm2, p14ARF, deltaNp73, and others. We are therefore pursuing the unique opportunity to re-establish p53‘s “dormant” tumor-suppressive activity by targeting its modulators as a potential avenue to therapy.


Application & Start your career

Way of application:
  • Apply via E-Mail


Founding year: 2005
Value of employees: 11-50
Expansion: national

In our company employees are working in the following fields:
Research & Development, Research & Education, Research Associate

In our company employees with these qualifications are welcome:
Biology & Life Sciences


Universitätsmedizin Göttingen
Abteilung Molekulare Onkologie, GZMB
Justus von Liebig Weg, Room 3.234 11
D-37077 Göttingen